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Aspirin reduces vascular death by approximately 15% and nonfatal vascular events by
about 30% in secondary prevention. The evidence in primary prevention in non-diabetic
subjects is not so powerful. The benefit of aspirin primary prevention in type 2 diabetes
remains to be advocated definitely.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Aspirin (acetylsalicylic acid, ASA) is an effective, time-tested
antithrombotic agent. Aspirin inhibits the production ofch Society of Cardiology.
4; fax: þ420 377 402 650.
.cz (B. Nussbaumerova´).thromboxane A , a potent platelet aggregation and vasocon-2
striction agent, by inhibiting the enzyme platelet cyclooxy-
genase (COX-1). Aspirin is usually administered in peroral
doses of 75–325mg daily. In secondary cardiovascularPublished by Elsevier Urban & Partner Sp.z o.o. All rights reserved..
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reduce the risk of vascular death by about 15% and the risk of
nonfatal myocardial infarction and stroke by about 30% in
patients with unstable angina, suspected acute myocardial
infarction, silent myocardial ischemia, or a past history of
myocardial infarction, coronary angioplasty, aortocoronary
bypass surgery, stroke, or a transient ischemic attack reliably
[1–5]. There are also sufficient data supporting the use of aspirin
in secondary prevention in diabetic subjects [6].
On the other hand, the administration of aspirin to asymp-
tomatic subjects without any manifested cardiovascular dis-
eases, i.e. primary prevention subjects, is not yet clear. There
is also some evidence of preventing myocardial infarction
in both males and females older than 50 years but not as
strong as in secondary cardiovascular prevention. There is no
powerful evidence of preventing vascular deaths by aspirin in
primary prevention. The evidence is also not really consistent
in diabetic subjects. Physicians prescribing aspirin to their
patients should be aware of possible adverse events that
can occur during the treatment; especially gastrointestinal
bleeds, intracerebral hemorrhage and hypersensitivity/allergy
to aspirin. Aspirin in primary prevention is definitely contra-
indicated in subjects with allergy to aspirin, with overall
tendency to bleed, with personal history of recent gastro-
intestinal bleeding, with active liver disease and under
21 years of age.2. Evidence on aspirin in primary prevention
In the past three decades, aspirin in primary prevention was
handled as ‘‘the golden standard’’ for many subjects with
some presence of cardiovascular risk and for subjects with
type 2 diabetes. A known prothrombogenic and proinflama-
tory state in diabetes might advocate the use of aspirin in
primary prevention because of the presence of high cardio-
vascular risk among these subjects [7,8]. Clinical guidelines
recommended strictly the administration of aspirin for both
primary and secondary cardiovascular prevention in diabetes;
e.g. the ones in our country, the Czech ‘‘Guidelines onTable 1 – The most important trials on aspirin in primary pre
PHS (1988) BDT (1988) TPT (1998)
Number of
subjects
22,071 5139 5085
Follow up
(years)
5 5.8 6.8
Population Healthy male
physicians
Healthy male
physicians
Males in high
risk of CHD
Age (years) 40–84 50–78 45–69
Males:
females (%)
100: 0 100: 0 100: 0
Aspirin
dose (mg)
325 OAD 500 D 75 D
Control Placebo No placebo Placebo
PHS—Physicians’ Health Study, BDT—British Doctors’ Trial, TPT—Thro
PPP—Primary Prevention Project, WHS—Women’s Health Study, OAD—oprevention of cardiovascular diseases in adults’’ (published in
2005) recommend the administration of aspirin or other
antiaggregation drug to all subjects with manifest cardiovas-
cular disease, type 2 diabetes, type 1 diabetes with micro-
albuminuria, cardiovascular risk according to SCORE risk
model over 5% and hypertensive subjects with a moderately
elevated creatinine level [9]. Nevertheless, clinical practice has
changed in the past about 4 years because newer emerging
surveys questioned the clinical benefit of such an approach.
The evidence for the aspirin administration in primary
prevention proceeds from larger and smaller surveys. The
largest ones with about 85,000 subjects, with the dose of
aspirin between 100 mg on alternate days and 500 mg daily
are summarized in Table 1 [10–15], i.e. the Physicians’ Health
Study (PHS), British Doctors’ Trial (BDT), Thrombosis Preven-
tion Trial (TPT), Hypertension Optimal Treatment (HOT) trial,
Primary Prevention Project (PPP) and Women’s Health Study
(WHS). The reduction of myocardial infarction was between
3% and 40% in the trials mentioned above. A metaanalysis of
these surveys (without WHS) in 1998 also reported a statisti-
cally significant 15% risk reduction of any important vascular
event associated with aspirin therapy (relative risk [RR]—0.85,
95% CI [confidence interval]¼0.79–0.93), driven in large part by
the statistically extreme finding of reduced myocardial infarc-
tion risk by 32% (RR 0.68, 95% CI¼0.59–0.79). No statistically
significant decrease was shown in total stroke overall (RR¼1.02,
95% CI¼0.85–1.23), maybe due to a low number of strokes and
an inexact definition of either ischemic or hemorrhagic stroke.
For vascular deaths, there was no significant reduction in risk
although the CIs were wide and included the plausible decrease
seen in the trials of secondary prevention, as well as a small
increase (RR¼0.98, 95% CI¼0.85–1.12) [16].
In 2005, the Women’s Health Study was published [15]. The
trial on 39,896 sole female participants looked at the use
of aspirin in primary prevention of cardiovascular events.
Aspirin (100 mg on alternate days) did not lower the risk
either of myocardial infarction or cardiovascular death over-
all, but it significantly reduced the risk of stroke by 17% in the
whole trial group (RR 0.83, 95% CI¼0.69–0.99, p¼0.04), owing
to a 24% reduction of the risk of ischemic stroke (RR 0.76, 95%vention.
HOT (1998) PPP (2001) WHS
(2005)
18,790 4495 39,876
3.8 3.6 10
Males and females
with hypertension
Males and females with 1
CHD risk factor
Females
50–80 50–480 440;
aver. 54
53: 47 42: 58 0: 100
75 D 100 D 100
OAD
Placebo No placebo Placebo
mbosis Prevention Trial, HOT—Hypertension Optimal Treatment,
n alternate days, D—daily, CHD—coronary heart disease.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 9 0 – e 1 9 5e192CI 0.63–0.93, p¼0.009) and a nonsignificant increase in the
risk of hemorrhagic stroke (RR 1.24, 95% CI 0.82–1.87, p¼0.31).
In women aged over 65, there was a significant benefit of
aspirin use compared to placebo. The risk of major cardio-
vascular events was reduced by 26% among those who were
on aspirin (RR 0.74, 95% CI 0.59–0.92, p¼0.008). The risk of
ischemic stroke was reduced by 30% (RR 0.70, 95% CI
0.49–1.00, p¼0.05). The risk of myocardial infarction was also
reduced by 34% (RR 0.66, 95% CI 0.44–0.97, p¼0.04). On the
other hand, aspirin failed to show any effect on cardiovas-
cular events in women aged 45–65. The dose of aspirin may
have been too low in this trial, as shown in the metaanalyses
of other trials mentioned above where the doses lower than
75 mg daily were not effective.
In 2009, the Antithrombotic Trialists’ Collaboration pub-
lished an individual patient-level metaanalysis of six large
trials on aspirin for primary prevention in the general
population [17]. These trials enrolled over 95,000 participants,
including almost 4000 with diabetes. Overall, this metaana-
lysis found that aspirin reduced the risk of vascular events by
12% (RR 0.88, 95% CI 0.82–0.94, p¼0.0001). The largest reduc-
tion was for nonfatal myocardial infarction (RR 0.77, 95%
CI 0.67–0.89, po0.0001). The net effect on stroke was not
significant (0.20% vs 0.21% per year, p¼0.4, hemorrhagic
stroke 0.04% vs 0.03%, p¼0.05, other stroke 0.16% vs
0.18% per year, p¼0.08). Vascular mortality did not differ
significantly (0.19% vs 0.19% per year, p¼0.7). The net effect
on total stroke reflected a relative reduction in risk of ischemic
stroke (14%) and a relative increased risk of hemorrhagic stroke
(32%). In this trial, aspirin allocation increased major gastro-
intestinal and extracranial bleeds (0.10% vs 0.07% per year,
po0.0001). Main risk factors were identical for coronary disease
and for bleeding.
The newest metaanalyses on aspirin in primary prevention
emerged in 2011 and 2012 [18,19]. The same fact was shown,
i.e. aspirin had no effect on vascular and total mortality and
had a protective effect on new onset of cardiovascular events
driven mainly by myocardial infarction. Nontrivial bleeds
were present significantly more often in the aspirin group
than in the placebo group in the second metaanalysis (OR
1.31, 95% CI 1.14–1.50, number needed to harm 73).3. Evidence on aspirin in diabetes in primary
prevention
The proportion of patients with diabetes mellitus was small
in each of the above mentioned primary preventive trials
with aspirin (PPP: 17%; HOT: 8%; PHS: 2%; BDT: 2%; and
TPT: 2%). Only in PHS, patients with diabetes derived greater
benefit from aspirin than those without diabetes in 41% RR
reduction of myocardial infarction in the 5 years follow up
(RR 0.59, 95% CI 0.33–1.06) [20].
In the Early Treatment Diabetic Retinopathy Study (ETDRS)
in which 3711 subjects with type 1 and 2 diabetes (majority of
them without any history of myocardial infarction or stroke)
were randomized to receive 650 mg aspirin daily or placebo
was not shown any positive effect of aspirin regarding total
mortality but some reduction in fatal and nonfatal myocar-
dial infarctions (RR 0.83, 99% CI¼0.66–1.04) [21].In a metaanalysis perfomed by the Antiplatelet Trialists’
Collaboration were included 4961 patients with diabetes in
nine trials. Antiplatelet therapy was associated with only
a 7% proportional reduction in serious vascular events [6].
None of the trials reported major extracranial bleeding.
There was a need to design surveys focused on diabetic
patients with no coronary heart disease separately. The
first ones emerged in 2008. The trial Prevention of Progression
of Arterial Disease and Diabetes (POPADAD) included
quite high-risk patients, with type 1 or type 2 diabetes and
peripheral artery disease (PAD). Secondary prevention could
be considered in these patients. Asymptomatic PAD was
determined by a lower-than-normal ankle-brachial pressure
index of 0.99 or less, but no symptoms. The subjects (n¼1276)
were older than 40 years and were randomized to receive
either aspirin 100 mg daily or placebo, and followed over 9
years. It was investigated whether aspirin could reduce set
primary end points: 1 death from coronary heart disease or
stroke, nonfatal myocardial infarction or stroke, or amputa-
tion above the ankle for critical limb ischemia; 2 and death
from coronary heart disease or stroke. Overall, there was
found no benefit from aspirin. Patients in both study groups
experienced the same number (116 and 117) of primary
events (hazard ratio [HR] 0.98, 95% CI¼0.76–1.26, p¼0.86).
There were 43 deaths from coronary heart disease or stroke
in the aspirin group compared with 35 in the placebo group
(HR 1.23, 95% CI¼0.79–1.93, p¼0.36). There was found no
evidence that aspirin was of any benefit in the primary
prevention of cardiovascular events in diabetic patients
with asymptomatic PAD [22]. Some say the study was under-
powered with only 1276 patients.
The trial Japanese Primary Prevention of Atherosclerosis with
Aspirin for Diabetes (JPAD) randomized 2539 patients aged
maximally 85 years with a good control of type 2 diabetes and
arterial hypertension of an average of 4.4 years follow up [23].
They did not have any history of atherosclerotic disease (struc-
tural or arrythmic cardiovascular disease, stroke and other
cerebrovascular diseases, peripheral vascular disease). The sub-
jects received aspirin at either 81mg daily or 100mg daily or
placebo on an open-label basis and did not receive either other
antiplatelet or anticoagulation drugs. Atherosclerotic eventswere
defined as sudden death; death from coronary, cerebrovascular,
or aortic causes; nonfatal myocardial infarction, unstable angina,
new exertional angina; nonfatal ischemic or hemorrhagic stroke;
transient ischemic attack; or nonfatal aortic or peripheral vas-
cular disease. After the median of 4.4 years follow up, there was
no significant difference in the new atherosclerotic events. A
total of 154 atherosclerotic events occurred with a nonsignificant
difference: 68 in the aspirin group and 86 in the nonaspirin group
(HR 0.80; 95% CI 0.58–1.10, p¼0.16). A total of 34 patients in the
aspirin group and 38 patients in the nonaspirin group died from
any cause (HR 0.90; 95% CI 0.57–1.14, p¼0.67). The combined end
point of fatal coronary events and fatal cerebrovascular events
occurred in 1 patient (stroke) in the aspirin group and 10 patients
(5 fatal myocardial infarctions and 5 fatal strokes) in the
nonaspirin group (HR 0.10, 95% CI 0.01–0.79, p¼0.0037) which
was the only one significant result in this study in fact. In a
subgroup analysis (1363 patients aged Z65 years), the group
of 719 subjects on aspirin showed a significant aspirin-related
decrease in risk of atherosclerotic events; younger patients
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stroke and serious gastrointestinal bleeding was not signifi-
cantly different between the aspirin and placebo groups.
One could summarize, there is available evidence on aspirin
in primary prevention of cardiovascular disease from three
trials focused on diabetics separately and six other large trials
including some number of diabetics up-to-date. None of these
trials provides definitive results and solutions. Several metaa-
nalyses of these trials provide different results according to
the trials included into each metaanalyse. The most limiting
fact is the low event rate in the control groups. One might
conclude aspirin is effective in a modest-sized reduction in
myocardial infarction and stroke in patients with diabetes, but
current evidence is not definite. The differences in outcomes
for males and females have to be further investigated. There
have also been too small totals of events in the performed
trials and we rely on analyses of subgroups within larger trials
to be able to make any conclusion.4. Recommendations in primary prevention
in the ‘‘new era of aspirin’’ after 2010
After the results of POPADAD and JPAD trails and the Anti-
thrombotic Trialists’ Collaboration’s metaanalysis on aspirin
use in primary prevention following Czech guidelines were
published. The Czech ‘‘Standards of Medical Care in Diabetes’’
from 2012 recommend to follow to administer aspirin (100 mg
daily) in primary prevention to diabetic subjects with other risks
and in secondary prevention, nevertheless, no exact definition
of ‘‘other risks’’ is given [24]. The newest Czech ‘‘Diagnostic and
therapeutic recommendations on arterial hypertension-
version 2012’’ support the allocation of aspirin in primary
prevention to those with arterial hypertension and a very high
cardiovascular risk according to SCORE risk model or with renal
impairment because of a doubtful ratio of risk and benefit of
aspirin in hypertensive subjects at low cardiovascular risk. A
routine admission of aspirin is not recommended in these
subjects [25].
In 2010, a Position Statement of the American Diabetes
Association (ADA), a Scientific Statement of the American
Heart Association (AHA), and an Expert Consensus Document
of the American College of Cardiology Foundation (ACCF) was
published [26].
Low-dose (75–162mg daily) aspirin use for primary prevention
is reasonable for adults with diabetes who are at increased
cardiovascular risk (10 years risk of cardiovascular events over
10% according to Framingham risk model) and who are not
at increased risk of bleeding (based on a history of previous
gastrointestinal bleeding or peptic ulcer disease or concurrent
use of other medications that increase bleeding risk, such as
nonsteroidal anti-inflammatory drugs [NSAIDS] or warfarin).
Those adults with diabetes at increased cardiovascular risk
include most males over age 50 years and females over age 60
years who have one or more of the following additional major
risk factors: smoking, arterial hypertension, dyslipidemia, family
history of premature cardiovascular disease, and albuminuria.
(ACCF/AHA Class IIa, Level of Evidence: B) (ADA Level of
Evidence: C).Aspirin should not be recommended for cardiovascular
prevention for adults with diabetes at low cardiovascular risk
(men under age 50 years and women under 60 years with no
major additional cardiovascular risk factors; 10-years cardio-
vascular risk under 5%) as the potential adverse effects from
bleeding offset the potential benefits. (ACCF/AHA Class III,
Level of Evidence: C) (ADA Level of Evidence: C).
Low-dose (75–162 mg/day) aspirin use for prevention might
be considered for those with diabetes at intermediate cardio-
vascular risk (younger patients with one or more risk factors,
or older subjects with no risk factors, or patients with 10-years
cardiovascular risk of 5–10%) until further research is available.
(ACCF/AHA Class IIb, Level of Evidence: C) (ADA Level of
Evidence: E).
There is a need of a proper cardiovascular risk assessment, as
a part of the decision-making process about aspirin allocation
because not all subjects with diabetes are at high cardiovascular
risk. We should consider the risk factors based on either a
combination of age, sex, and other risk factors or on an estimate
of absolute cardiovascular risk. The cardiovascular risk should
be reassessed over time. It is possible to use several tools for
cardiovascular risk estimation in diabetics [27–29].
The European Guidelines on cardiovascular disease preven-
tion in clinical practice (version 2012), the Fifth Joint Task
Force of the European Society of Cardiology and Other
Societies on Cardiovascular Disease Prevention in Clinical
Practice (constituted by representatives of nine societies and
by invited experts) developed with the special contribution of
the European Association for Cardiovascular Prevention &
Rehabilitation (EACPR) say simply aspirin cannot be recom-
mended in primary prevention [30].5. Results of our research
In our department, a group of 415 outpatients with type 2
diabetes has been followed in the frame of a clinical research
project since 2005 [31,32]. In the beginning, these 219 males
and 196 females were aged 6679 years and 95% were
hypertensive; 28% (n¼116) had atherosclerotic complications,
i.e. coronary heart disease, stroke, transient ischemic attack,
symptomatic carotid stenosis or peripheral artery disease
(these pathologies were also considered as end points in the
follow-up); 55% of atherosclerotic complications were coron-
ary heart disease, significantly more often in males, po0.01;
54% (n¼224) had microvascular complications i.e. neuro-
pathy, nephropathy, and retinopathy; 95% of microvascular
complications were diabetic nephropathy, no difference
between sexes; 40% (n¼167, no difference between sexes)
had no vascular complications. The subjects with athero-
sclerotic complications had more often microvascular com-
plications. The subjects with presence of any complications
had a worse risk profile than the ones without any complica-
tions. The risk factors associated independently and signifi-
cantly with atherosclerotic complications were male gender,
age over 60 years, a higher level of high-sensitivity C-reactive
protein (hs-CRP)41 mg/l, glycemia45.6 mmol/l, lower diasto-
lic blood pressure and lower HDL-cholesterol. The risk factors
associated independently and significantly with
Table 2 – Basic characteristics of the sample of asymptomatic diabetics.
Parameter Value (7SD)
N (males/females) 143/156
Age (years) 6279
Diabetes history (years) 8.477.7
BMI (kg/m2) 3176
Waist circumference (cm) 107713
Systolic blood pressure (mm Hg) 144717
Diastolic blood pressure (mm Hg) 80717
LDL-cholesterol (mmol/l) 3.2670.91
HDL-cholesterol (mmol/l) 1.1670.25
Triglycerides (mmol/l) 2.0871.73
Fasting glycemia (mmol/l) 9.3273.35
Hemoglobin A1c (mmol/mol, IFCC) 60717.6
SD—standard deviation, IFCC—International Federation of Clinical Chemistry and Laboratory Medicine.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 9 0 – e 1 9 5e194microvascular complications were age over 60 years, history
of diabetes exceeding 8 years and hs-CRP41 mg/l.
Our research was not primarily focused on aspirin treatment.
Nevertheless, we can provide some data on aspirin administra-
tion in primary prevention of any vascular complications in
diabetics. The characteristics of the subgroup ‘‘asymptomatic’’
(n¼299), i.e. without any manifestation of atherosclerotic com-
plications are given in Table 2. In such a sample of 143males and
156 females aspirin was given to 29 males (20%) and 24 females
(15%). After a 5 years follow up, there were 3 deaths from
vascular causes in the aspirin group (1 male and 2 females,
5.6% of the aspirin group) and 12 deaths in the nonaspirin group
(6 males and 6 females, 4.8% of the non-aspirin group). New
end points (as mentioned above) developed in 15 subjects in the
aspirin group (7 males and 8 females, 28% of the aspirin group)
and 53 subjects in the nonaspirin group (21 males and 32
females, 22% of the nonaspirin group). From the group ‘‘asymp-
tomatic’’ there were 94 males and 108 females left in 2012 (the
difference in totals died from nonvascular causes or was lost),
fromwhich 13males (14%) and 14 females (13%) were on aspirin.
We are aware our observed cohort of patients was small, it does
not allow statistically validated conclusions and serves only to
information about the problem.6. Final conclusion
According to the above mentioned information, we try to
answer the question whether there is any difference between
aspirin use in diabetic and non-diabetic subjects in primary
prevention. In general, the difference is not very distinctive.
We have to assess the global cardiovascular risk properly,
follow the available evidence for every particular group of
patients and then decide carefully whether to start or not the
aspirin allocation. We have to consider the protective effects of
aspirin treatment on one side and the bleeding risk on the other;
i.e. individualized treatment is necessary for every patient in
primary prevention of cardiovascular diseases. More data from
randomized controlled trials are needed for the primary preven-
tion of atherosclerotic vascular events, especially in subjects at
high and moderate global cardiovascular risk.r e f e r e n c e s
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